Q-omics provides the consensus-scored FMO10P profile across patient tissues and cancer cell-line models. FMO10P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FMO10P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, FMO10P RNA expression shows 6,225 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, HNSC, and STAD as cancer lineages where FMO10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FMO10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FMO10P survival associations across molecular data types. FMO10P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FMO10P RNA expression–survival associations across cancer types. High FMO10P expression shows unfavorable associations in BRCA, STAD, LIHC, KIRC, COAD and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for FMO10P RNA expression.
This table summarizes FMO10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FMO10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FMO10P shows higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher FMO10P RNA expression in tumor versus normal tissue (log2 FC = +0.010, t-test p = .030).
This table shows molecular features associated with FMO10P in patient tissues and cancer cell lines. In patient samples, FMO10P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
